Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 2/20 | 0.59 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.59 |
| ▸ | BCR | P11274 | 2/20 | 0.59 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.59 |
| ▸ | PRKCA | P17252 | 2/20 | 0.59 |
| ▸ | EGFR | P00533 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | SGMS2 | Q8NHU3 | 5/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4902752 | 0.84 | ALDH1A1 (0.54) | MAPTKDM4EKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL716307 | 0.82 | KDM4E (0.52) | ABL1PDGFRBBCRPDGFRAPRKCA | |
| SCHEMBL5503213 | 0.82 | ABL1 (0.51) | ABL1PDGFRBBCRPDGFRAPRKCA | |
| SCHEMBL717582 | 0.81 | ABL1 (0.48) | ABL1PDGFRBBCRPDGFRAPRKCA | |
| SCHEMBL718546 | 0.81 | ABL1 (0.49) | ABL1PDGFRBBCRPDGFRAPRKCA | |
| SCHEMBL714837 | 0.78 | NPC1 (0.53) | ABL1PDGFRBBCRPDGFRAEGFR | |
| SCHEMBL716174 | 0.78 | KDM4E (0.54) | ABL1PDGFRBBCRPDGFRAMAPT | |
| SCHEMBL718339 | 0.77 | RAB9A (0.44) | ABL1PDGFRBBCRPDGFRAEGFR | |
| SCHEMBL718122 | 0.77 | ABL1 (0.58) | ABL1PDGFRBBCRPDGFRAEGFR | |
| SCHEMBL14789747 | 0.75 | ABL1 (0.74) | ABL1PDGFRBBCRPDGFRAEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993573-B2 | 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors | AB SCIENCE (FR) | 2015-03-31 | — | — | US | disclosed |
| US-8835435-B2 | 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors | AB SCIENCE (FR) | 2014-09-16 | — | — | US | disclosed |
| US-20140088108-A1 | 2-(3-AMINOARYL) AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITIORS | AB SCIENCE (FR) | 2014-03-27 | — | — | US | disclosed |
| US-8450302-B2 | 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors | AB SCIENCE (FR) | 2013-05-28 | — | — | US | disclosed |
| US-20120053186-A1 | 2-(3-AMINOARYL) AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS | AB SCIENCE (FR) | 2012-03-01 | — | — | US | disclosed |
| US-20110201620-A1 | 2-(3-AMINOARYL) AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS | AB SCIENCE (FR) | 2011-08-18 | — | — | US | disclosed |
| US-20080255141-A1 | Modulators of signal transduction mediated by certain native and/or mutant tyrosine kinases; antiproliferative, anticarcinogenic, antiallergen, and antiinflammatory agents; metabolic and neurodegenerative disorders | AB SCIENCE | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053186-A1 | 2-(3-AMINOARYL) AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS | KIT, CHUK, MAP3K2 | ABL1 40/4885PDGFRB 38/4885BCR 226/4885 |
| US-20110201620-A1 | 2-(3-AMINOARYL) AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS | KIT, ABL1, MUSK | ABL1 2/4885PDGFRB 89/4885BCR 746/4885 |
| US-20140088108-A1 | 2-(3-AMINOARYL) AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITIORS | KIT, CHUK, CKS1B | ABL1 22/4885PDGFRB 41/4885BCR 167/4885 |
| US-20080255141-A1 | Modulators of signal transduction mediated by certain native and/or mutant tyrosine kinases; antiproliferative, anticarcinogenic, antiallergen, and antiinflammatory agents; metabolic and neurodegenerative disorders | KIT, MAP3K1, MAP3K6 | ABL1 176/4885PDGFRB 203/4885BCR 389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.